In a phase 1 study, the dual BCL2 and BCL2L1 (BCL-xL) inhibitor navitoclax demonstrated on-target activity, but with the off-tumor effect of thrombocytopenia [19]. The gene discussed is BCL2L1; the disease is Thrombocytopenia.